Thoma Bravo, a software investment firm, completed the investment in Bluesight, a medical firm, and Medacist, a pioneer in drug diversion monitoring. Financial terms were not disclosed. "More than 25 years ago, we embarked on a mission to revolutionize healthcare with a new approach to identifying and preventing drug diversion. Since its inception, Medacist has been a trailblazer, helping to identify potential cases of drug diversion across thousands of healthcare organizations. Medacist is thrilled to partner with Bluesight and Thoma Bravo to accelerate our impact," David Brzozowski, Sr., Medacist President and CEO.